Email ID
Password
Sign me in automatically next time
Actelion hit by negative Tracleer data
02 March 2010
Asher Mullard

Asher.mullard@informa.com

Actelion's Tracleer (bosentan) failed to reduce morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF), show top-line Phase III trial results of the BUILD-3 trial. The Swiss company says that it will not carry out any future trials with the endothelin receptor antagonist in...



Please Login to read the full article.
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36